These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 34845311)

  • 1. Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes.
    Palma G; Khurshid F; Lu K; Woodward B; Husain H
    NPJ Precis Oncol; 2021 Nov; 5(1):98. PubMed ID: 34845311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review.
    Santarpia M; Ciappina G; Spagnolo CC; Squeri A; Passalacqua MI; Aguilar A; Gonzalez-Cao M; Giovannetti E; Silvestris N; Rosell R
    Transl Lung Cancer Res; 2023 Feb; 12(2):346-368. PubMed ID: 36895930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CodeBreaK 200: Sotorasib (AMG510) Has Broken the
    Brazel D; Kim J; Ou SI
    Lung Cancer (Auckl); 2023; 14():31-39. PubMed ID: 37101896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.
    Mausey N; Halford Z
    Ann Pharmacother; 2024 Jun; 58(6):622-635. PubMed ID: 37700573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
    Bungaro M; Novello S; Passiglia F
    Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural insights into small-molecule KRAS inhibitors for targeting KRAS mutant cancers.
    Pandey D; Chauhan SC; Kashyap VK; Roy KK
    Eur J Med Chem; 2024 Nov; 277():116771. PubMed ID: 39167893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting
    Ji J; Wang C; Fakih M
    Onco Targets Ther; 2022; 15():747-756. PubMed ID: 35837349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
    Chen Y; Liu QP; Xie H; Ding J
    Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.
    Cekani E; Epistolio S; Dazio G; Cefalì M; Wannesson L; Frattini M; Froesch P
    Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy.
    Shu CL; Liu YL
    Cancer Manag Res; 2022; 14():3485-3492. PubMed ID: 36561983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report.
    Iska S; Alley EW
    Case Rep Oncol; 2023; 16(1):177-181. PubMed ID: 37008835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
    Parums DV
    Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer.
    Karachaliou A; Kotteas E; Fiste O; Syrigos K
    Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
    Reck M; Carbone DP; Garassino M; Barlesi F
    Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
    Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
    J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives.
    Li JX; Li RZ; Ma LR; Wang P; Xu DH; Huang J; Li LQ; Tang L; Xie Y; Leung EL; Yan PY
    Front Pharmacol; 2022; 13():875330. PubMed ID: 35517800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting
    Désage AL; Léonce C; Swalduz A; Ortiz-Cuaran S
    Front Oncol; 2022; 12():796832. PubMed ID: 35251972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TEAD Inhibitors Sensitize KRAS
    Tammaccaro SL; Prigent P; Le Bail JC; Dos-Santos O; Dassencourt L; Eskandar M; Buzy A; Venier O; Guillemot JC; Veeranagouda Y; Didier M; Spanakis E; Kanno T; Cesaroni M; Mathieu S; Canard L; Casse A; Windenberger F; Calvet L; Noblet L; Sidhu S; Debussche L; Moll J; Valtingojer I
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.
    Rathod LS; Dabhade PS; Mokale SN
    Drug Discov Today; 2023 May; 28(5):103557. PubMed ID: 36934967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.